These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

467 related items for PubMed ID: 12030110

  • 1. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, 5-fluorouracil and cis-retinoic acid in the treatment of renal cell carcinoma: final results of cancer biotherapy research group 94-10.
    Soori G, Dillman RO, Wiemann MC, Stark JJ, Tai F, DePriest CB, Church CK, Schulof R.
    Cancer Biother Radiopharm; 2002 Apr; 17(2):165-73. PubMed ID: 12030110
    [Abstract] [Full Text] [Related]

  • 2. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: final results of cancer biotherapy research group 94-11.
    Dillman RO, Soori G, Wiemann MC, Schulof R, Dobbs TW, Ruben RH, DePriest CB, Church C.
    Cancer Biother Radiopharm; 2000 Oct; 15(5):487-94. PubMed ID: 11155820
    [Abstract] [Full Text] [Related]

  • 3. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
    Dutcher JP, Logan T, Gordon M, Sosman J, Weiss G, Margolin K, Plasse T, Mier J, Lotze M, Clark J, Atkins M.
    Clin Cancer Res; 2000 Sep; 6(9):3442-50. PubMed ID: 10999727
    [Abstract] [Full Text] [Related]

  • 4. Phase II trial of subcutaneous interferon followed by intravenous hybrid bolus/continuous infusion interleukin-2 in the treatment of renal cell carcinoma: final results of Cancer Biotherapy Research Group 95-09.
    Dillman RO, Wiemann MC, Tai DF, Depriest CB, Soori G, Stark JJ, Mahdavi K, Church CK.
    Cancer Biother Radiopharm; 2006 Apr; 21(2):130-7. PubMed ID: 16706633
    [Abstract] [Full Text] [Related]

  • 5. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.
    van Herpen CM, Jansen RL, Kruit WH, Hoekman K, Groenewegen G, Osanto S, De Mulder PH.
    Br J Cancer; 2000 Feb; 82(4):772-6. PubMed ID: 10732744
    [Abstract] [Full Text] [Related]

  • 6. [Impact of immunochemotherapy on survival of patients with metastatic renal cell carcinoma. A retrospective study comparing interferon-alpha-2a/vinblastine versus interferon-alpha-2a/interleukin-2/5-fluorouracil].
    May M, Helke C, Bock M, Hoschke B.
    Urologe A; 2004 Sep; 43(9):1111-9. PubMed ID: 15232686
    [Abstract] [Full Text] [Related]

  • 7. Interleukin-2, interferon-alpha, 5-fluorouracil, and vinblastine in the treatment of metastatic renal cell carcinoma: a prospective phase II study: the experience of Rambam and Lin Medical Centers 1996-2000.
    Gez E, Rubinov R, Gaitini D, Meretyk S, Best LA, Native O, Stein A, Erlich N, Beny A, Zidan J, Haim N, Kuten A.
    Cancer; 2002 Oct 15; 95(8):1644-9. PubMed ID: 12365011
    [Abstract] [Full Text] [Related]

  • 8. Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subcutaneous Administration Propeukin Program Cooperative Group.
    Tourani JM, Pfister C, Berdah JF, Benhammouda A, Salze P, Monnier A, Paule B, Guillet P, Chretien Y, Brewer Y, Di Palma M, Untereiner M, Malaurie E, Tadrist Z, Pavlovitch JM, Hauteville D, Mejean A, Azagury M, Mayeur D, Lucas V, Krakowski I, Larregain-Fournier D, Abourachid H, Andrieu JM, Chastang C.
    J Clin Oncol; 1998 Jul 15; 16(7):2505-13. PubMed ID: 9667271
    [Abstract] [Full Text] [Related]

  • 9. Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study.
    Allen MJ, Vaughan M, Webb A, Johnston S, Savage P, Eisen T, Bate S, Moore J, Ahern R, Gore ME.
    Br J Cancer; 2000 Oct 15; 83(8):980-5. PubMed ID: 10993642
    [Abstract] [Full Text] [Related]

  • 10. Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).
    Atzpodien J, Kirchner H, Jonas U, Bergmann L, Schott H, Heynemann H, Fornara P, Loening SA, Roigas J, Müller SC, Bodenstein H, Pomer S, Metzner B, Rebmann U, Oberneder R, Siebels M, Wandert T, Puchberger T, Reitz M, Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).
    J Clin Oncol; 2004 Apr 01; 22(7):1188-94. PubMed ID: 14981107
    [Abstract] [Full Text] [Related]

  • 11. Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Français d'Immunothérapie, Fédération Nationale des Centres de Lutte Contre le Cancer.
    Négrier S, Caty A, Lesimple T, Douillard JY, Escudier B, Rossi JF, Viens P, Gomez F.
    J Clin Oncol; 2000 Dec 15; 18(24):4009-15. PubMed ID: 11118461
    [Abstract] [Full Text] [Related]

  • 12. Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial. Groupe Français d'Immunothérapie.
    Ravaud A, Audhuy B, Gomez F, Escudier B, Lesimple T, Chevreau C, Douillard JY, Caty A, Geoffrois L, Ferrero JM, Linassier C, Drevon M, Négrier S.
    J Clin Oncol; 1998 Aug 15; 16(8):2728-32. PubMed ID: 9704724
    [Abstract] [Full Text] [Related]

  • 13. Phase II studies of antiangiogenic four drug regimens for the treatment of advanced renal cell carcinoma: FUNIL-retinoid and the FUNIL-thalidomide protocols.
    Pacheco AV, Rasila K, Lee SJ, Rabinowitz I, Elias L, Lee FC, Verschraegen CF.
    Urol Oncol; 2008 Aug 15; 26(6):610-5. PubMed ID: 18367103
    [Abstract] [Full Text] [Related]

  • 14. Infusional interleukin-2 and 5-fluorouracil with subcutaneous interferon-alpha for the treatment of patients with advanced renal cell carcinoma: a southwest oncology group Phase II study.
    Elias L, Lew D, Figlin RA, Flanigan RC, Thompson ME, Triozzi PL, Belt RJ, Wood DP, Rivkin SE, David E.
    Cancer; 2000 Aug 01; 89(3):597-603. PubMed ID: 10931459
    [Abstract] [Full Text] [Related]

  • 15. Thirteen-year, long-term efficacy of interferon 2alpha and interleukin 2-based home therapy in patients with advanced renal cell carcinoma.
    Atzpodien J, Hoffmann R, Franzke M, Stief C, Wandert T, Reitz M.
    Cancer; 2002 Sep 01; 95(5):1045-50. PubMed ID: 12209689
    [Abstract] [Full Text] [Related]

  • 16. Phase I/II trial of outpatient PEG-interferon with interleukin-2 in advanced renal cell carcinoma: a cytokine working group study.
    Clark JI, Mehrabi J, Sosman JA, Logan TF, Margolin KA, Dutcher JP, Urba WJ, Ernstoff MS, McDermott DF, Lau AM, Atkins MB.
    J Immunother; 2007 Sep 01; 30(8):839-46. PubMed ID: 18049336
    [Abstract] [Full Text] [Related]

  • 17. Combination therapy with capecitabine and interferon alfa-2A in patients with advanced renal cell carcinoma: a phase II study.
    Padrik P, Leppik K, Arak A.
    Urol Oncol; 2004 Sep 01; 22(5):387-92. PubMed ID: 15464918
    [Abstract] [Full Text] [Related]

  • 18. Phase I/II trial of subcutaneous interleukin-2, granulocyte-macrophage colony-stimulating factor and interferon-α in patients with metastatic renal cell carcinoma.
    Garcia JA, Mekhail T, Elson P, Wood L, Bukowski RM, Dreicer R, Rini BI.
    BJU Int; 2012 Jan 01; 109(1):63-9. PubMed ID: 21244601
    [Abstract] [Full Text] [Related]

  • 19. Subcutaneous interleukin-2 and interferon-alpha in metastatic renal cell carcinoma: results of a French regional experience in Languedoc.
    Culine S, Iborra F, Mottet N, Avancès C, de Graeve B, Volpé P, Vignoud J, Bringer JP, Marroncle M, Le Pellec L, Ayuso D, Jansen E, Faix A, Rebillard X.
    Am J Clin Oncol; 2006 Apr 01; 29(2):148-52. PubMed ID: 16601433
    [Abstract] [Full Text] [Related]

  • 20. Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma.
    Figlin RA, Belldegrun A, Moldawer N, Zeffren J, deKernion J.
    J Clin Oncol; 1992 Mar 01; 10(3):414-21. PubMed ID: 1482425
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.